The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy

References

• JerusalemGBachelotTBarriosCA new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(−) advanced breast cancerCancer Treat Rev20154129410425575443
   PubMed Web of Science ®Google Scholar
• SchulzMIwersen-BergmannSAndresenHSchmoldtATherapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobioticsCrit Care2012164R13622835221
   PubMed Web of Science ®Google Scholar
• SalaczMEKastRESakiNBrüningAKarpel-MasslerGHalatschMEToward a noncytotoxic glioblastoma therapy: blocking MCP-1 with the MTZ regimenOnco Targets Ther201692535254527175087
   PubMed Web of Science ®Google Scholar
• ZapletalovaDAndreNDeakLMetronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experienceOncology201282524926022538363
   PubMed Web of Science ®Google Scholar
• KastREBoockvarJABrüningAA conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma CareOncotarget20134450253023594434
   PubMedGoogle Scholar
• KastREKarpel-MasslerGHalatschMECUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomideOncotarget20145188052808225211298
   PubMed Web of Science ®Google Scholar
• CheboutiIKasimir-BauerSBuderathPEMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapyOncotarget Epub201731410.18632/oncotarget.16179
   Google Scholar
• JinXJiangYZChenSYuKDShaoZMDiGHPrognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational studyOncotarget20156119600961125826079
   PubMedGoogle Scholar
• TossAVenturelliMPeterleCPiacentiniFCascinuSCortesiLMolecular biomarkers for prediction of targeted therapy response in metastatic breast cancer: trick or treat?Int J Mol Sci2017181E8510.3390/ijms1801008528054957
   PubMed Web of Science ®Google Scholar
• SambiMHaqSSamuelVAlternative therapies for metastatic breast cancer: multimodal approach targeting tumor cell heterogeneityBreast Cancer (Dove Med Press)20179859328280388
   PubMed Web of Science ®Google Scholar
• JonssonVDBlakelyCMLinLNovel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolutionSci Rep201774420628287179
   PubMed Web of Science ®Google Scholar
• BlakelyCMWatkinsTBKWuWEvolution and clinical impact of genetic epistasis within EGFR-mutant lung cancersbioRxiv2017 Available from: http://biorxiv.org/content/biorxiv/early/2017/03/16/117291.full.pdfAccessed March 16, 2017
   Google Scholar
• YeungKTYangJEpithelial-mesenchymal transition in tumor metastasisMol Oncol2017111283928085222
   PubMed Web of Science ®Google Scholar
• CreightonCJGibbonsDLKurieJMThe role of epithelial-mesenchymal transition programming in invasion and metastasis: a clinical perspectiveCancer Manag Res2013518719523986650
   PubMedGoogle Scholar
• WuYSarkissyanMVadgamaJVEpithelial-mesenchymal transition and breast cancerJ Clin Med201652E1326821054
   PubMed Web of Science ®Google Scholar
• MockKPrecaBTBrummerTBrabletzSStemmlerMPBrabletzTThe EMT-activator ZEB1 induces bone metastasis associated genes including BMP-inhibitorsOncotarget2015616143991441225973542
   PubMed Web of Science ®Google Scholar
• PrecaBTBajdakKMockKA novel ZEB1/HAS2 positive feedback loop promotes EMT in breast cancerOncotarget201787115301154328086235
   PubMedGoogle Scholar
• TanEJOlssonAKMoustakasAReprogramming during epithelial to mesenchymal transition under the control of TGFβCell Adh Migr20159323324625482613
   PubMed Web of Science ®Google Scholar
• SatoRSembaTSayaHArimaYConcise review: stem cells and epithelial-mesenchymal transition in cancer: biological implications and therapeutic targetsStem Cells20163481997200727251010
   PubMed Web of Science ®Google Scholar
• ChafferCLSan JuanBPLimEWeinbergRAEMT, cell plasticity and metastasisCancer Metastasis Rev201635464565427878502
   PubMed Web of Science ®Google Scholar
• YeungSFTongJHLawPPProfiling of oncogenic driver events in lung adenocarcinoma revealed MET mutation as independent prognostic factorJ Thorac Oncol20151091292130026098749
   PubMed Web of Science ®Google Scholar
• LeeYJungWHKooJSAdipocytes can induce epithelial-mesenchymal transition in breast cancer cellsBreast Cancer Res Treat2015153232333526285644
   PubMed Web of Science ®Google Scholar
• IngthorssonSBriemEBergthorssonJTGudjonssonTEpithelial plasticity during human breast morphogenesis and cancer progressionJ Mammary Gland Biol Neoplasia2016213–413914827815674
   PubMed Web of Science ®Google Scholar
• BulfoniMGerratanaLDel BenFIn patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosisBreast Cancer Res20161813026961140
   PubMed Web of Science ®Google Scholar
• BaeYKChoiJEKangSHLeeSJEpithelial-mesenchymal transition phenotype is associated with clinicopathological factors that indicate aggressive biological behavior and poor clinical outcomes in invasive breast cancerJ Breast Cancer201518325626326472976
   PubMed Web of Science ®Google Scholar
• JinMSHyunCLParkIASIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancerTumour Biol20163744743475326515337
   PubMedGoogle Scholar
• KotiyalSBhattacharyaSEpithelial mesenchymal transition and vascular mimicry in breast cancer stem cellsCrit Rev Eukaryot Gene Expr201525326928026558950
   PubMed Web of Science ®Google Scholar
• WuZHTaoZHZhangJMiRNA-21 induces epithelial to mesenchymal transition and gemcitabine resistance via the PTEN/AKT pathway in breast cancerTumour Biol20163767245725426666820
   PubMedGoogle Scholar
• ScimecaMAntonacciCColomboDBonfiglioRBuonomoOCBonannoEEmerging prognostic markers related to mesenchymal characteristics of poorly differentiated breast cancersTumour Biol20163745427543526563370
   PubMedGoogle Scholar
• BhowmikSKRamirez-PenaEArnoldJMEMT-induced metabolite signature identifies poor clinical outcomeOncotarget2015640426514266026315396
   PubMedGoogle Scholar
• Fernandez-GarciaBEiroNMarinLExpression and prognostic significance of fibronectin and matrix metalloproteases in breast cancer metastasisHistopathology20146451252224117661
   PubMed Web of Science ®Google Scholar
• ZhouXZhangJYunHAlterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer: tumor heterogeneity should be taken into considerationOncotarget2015634368943690226384297
   PubMedGoogle Scholar
• ParkSYKimMJParkSACombinatorial TGF-beta attenuation with paclitaxel inhibits the epithelial-to-mesenchymal transition and breast cancer stem-like cellsOncotarget2015635375263754326462028
   PubMedGoogle Scholar
• ChoiHSChoSGKimMKSH003 enhances paclitaxel chemosensitivity in MCF-7/PAX breast cancer cells through inhibition of MDR1 activityMol Cell Biochem20174261–21827854072
   PubMed Web of Science ®Google Scholar
• XuJLiuDNiuHResveratrol reverses doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/Akt signaling pathway in gastric cancerJ Exp Clin Cancer Res20173611928126034
   PubMed Web of Science ®Google Scholar
• YoshimasuTOhashiTOuraSA theoretical model for the hormetic dose-response curve for anticancer agentsAnticancer Res201535115851585526504007
   PubMed Web of Science ®Google Scholar
• MathengeEGDeanCAClementsDCore needle biopsy of breast cancer tumors increases distant metastases in a mouse modelNeoplasia2014161195096025425969
   PubMed Web of Science ®Google Scholar
• SzalayovaGOgrodnikASpencerBHuman breast cancer biopsies induce eosinophil recruitment and enhance adjacent cancer cell proliferationBreast Cancer Res Treat2016157346147427249999
   PubMed Web of Science ®Google Scholar
• JuratliMASiegelERNedosekinDAIn vivo long-term monitoring of circulating tumor cells fluctuation during medical interventionsPLoS One2015109e013761326367280
   PubMed Web of Science ®Google Scholar
• KaigorodovaEVTarabanovskayaNAStaheevaMNEffect of small and radical surgical injury on the level of different populations of circulating tumor cells in the blood of breast cancer patientsNeoplasma201764343744310.4149/neo_2017_31528253723
   PubMed Web of Science ®Google Scholar
• TsumuraHSatohTIshiyamaHPerioperative search for circulating tumor cells in patients undergoing prostate brachytherapy for clinically nonmetastatic prostate cancerInt J Mol Sci2017181E12828085051
   PubMed Web of Science ®Google Scholar
• HaraNKasaharaTKawasakiTFrequency of PSA-mRNA-bearing cells in the peripheral blood of patients after prostate biopsyBr J Cancer200185455756211506496
   PubMed Web of Science ®Google Scholar
• DyavanagoudarSKaleABhatKHallikerimathSReverse transcriptase polymerase chain reaction study to evaluate dissemination of cancer cells into circulation after incision biopsy in oral squamous cell carcinomaIndian J Dent Res200819431531919075434
   PubMedGoogle Scholar
• KusukawaJSuefujiYRyuFNoguchiRIwamotoOKameyamaTDissemination of cancer cells into circulation occurs by incisional biopsy of oral squamous cell carcinomaJ Oral Pathol Med200029730330710947245
   PubMed Web of Science ®Google Scholar
• MoncharmontCLevyAGuyJBRadiation-enhanced cell migration/invasion process: a reviewCrit Rev Oncol Hematol201492213314224908570
   PubMed Web of Science ®Google Scholar
• LeeHMHwangKAChoiKCDiverse pathways of epithelial mesenchymal transition related with cancer progression and metastasis and potential effects of endocrine disrupting chemicals on epithelial mesenchymal transition processMol Cell Endocrinol Epub20161229
   Web of Science ®Google Scholar
• KastREHillQAWionDGlioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: potential therapeutic benefit from dapsone, fenofibrate, and ribavirinTumour Biol2017395 101042831769979710.1177/1010428317699797
   Google Scholar
• Leyland-JonesBBondarenkoINemsadzeGA randomized, open-label, multicenter, phase III study of epoetin alfa versus best standard of care in anemic patients with metastatic breast cancer receiving standard chemotherapyJ Clin Oncol201634111197120726858335
   PubMed Web of Science ®Google Scholar
• VilaltaMRafatMGiacciaAJGravesEERecruitment of circulating breast cancer cells is stimulated by radiotherapyCell Rep20148240240925017065
   PubMed Web of Science ®Google Scholar
• KimRKKaushikNSuhYRadiation driven epithelial-mesenchymal transition is mediated by Notch signaling in breast cancerOncotarget2016733534305344227462787
   PubMedGoogle Scholar
• LeeSYJeongEKJuMKInduction of metastasis, cancer stem cell phenotype, and oncogenic metabolism in cancer cells by ionizing radiationMol Cancer20171611028137309
   PubMed Web of Science ®Google Scholar
• ZhaoRCaiZLiSExpression and clinical relevance of epithelial and mesenchymal markers in circulating tumor cells from colorectal cancerOncotarget2017869293930228030836
   PubMedGoogle Scholar
• ZhengXFanLZhouPDetection of circulating tumor cells and circulating tumor microemboli in gastric cancerTransl Oncol201710343144128448959
   PubMed Web of Science ®Google Scholar
• ZhangDZhaoLZhouPCirculating tumor microemboli (CTM) and vimentin+ circulating tumor cells (CTCs) detected by a size-based platform predict worse prognosis in advanced colorectal cancer patients during chemotherapyCancer Cell Int201717628070168
   PubMed Web of Science ®Google Scholar
• KolblACJeschkeUAndergassenUThe significance of epithelial-to-mesenchymal transition for circulating tumor cellsInt J Mol Sci2016178E130827529216
   PubMed Web of Science ®Google Scholar
• KieselLKohlARole of the RANK/RANKL pathway in breast cancerMaturitas201686101626921922
   PubMed Web of Science ®Google Scholar
• WangHShenWHuXQuetiapine inhibits osteoclastogenesis and prevents human breast cancer-induced bone loss through suppression of the RANKL-mediated MAPK and NF-κB signaling pathwaysBreast Cancer Res Treat2015149370571425667102
   PubMed Web of Science ®Google Scholar
• PalafoxMFerrerIPellegriniPRANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasisCancer Res201272112879288822496457
   PubMed Web of Science ®Google Scholar
• BeleutMRajaramRDCaikovskiMTwo distinct mechanisms underlie progesterone-induced proliferation in the mammary glandProc Natl Acad Sci U S A201010772989299420133621
   PubMed Web of Science ®Google Scholar
• KanCVargasGPapeFLClézardinPCancer cell colonisation in the bone microenvironmentInt J Mol Sci20161710E167427782035
   PubMed Web of Science ®Google Scholar
• YonedaTTanakaSHataKRole of RANKL/RANK in primary and secondary breast cancerWorld J Orthop20134417818524147253
   PubMedGoogle Scholar
• FutakuchiMFukamachiKSuzuiMHeterogeneity of tumor cells in the bone microenvironment: mechanisms and therapeutic targets for bone metastasis of prostate or breast cancerAdv Drug Deliv Rev201699pt B20621126656603
   PubMed Web of Science ®Google Scholar
• LamoraATalbotJMullardMBrounais-Le RoyerBRediniFVerrecchiaFTGF-β signaling in bone remodeling and osteosarcoma progressionJ Clin Med2016511E9627827889
   PubMed Web of Science ®Google Scholar
• KingTEJrBradfordWZCastro-BernardiniSASCEND Study GroupA phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosisN Engl J Med2014370222083209224836312
   PubMed Web of Science ®Google Scholar
• NathanSDAlberaCBradfordWZEffect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosisThorax201671542943526968970
   PubMed Web of Science ®Google Scholar
• ConteEGiliEFagoneEFrucianoMIemmoloMVancheriCEffect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblastsEur J Pharm Sci201458131924613900
   PubMed Web of Science ®Google Scholar
• DuJPazKFlynnRPirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-beta productionBlood2017129182570258028254742
   PubMed Web of Science ®Google Scholar
• StahnkeTKowtharapuBSStachsOSuppression of TGF-beta pathway by pirfenidone decreases extracellular matrix deposition in ocular fibroblasts in vitroPLoS One2017122e017259228231275
   PubMed Web of Science ®Google Scholar
• DidiasovaMSinghRWilhelmJPirfenidone exerts antifibrotic effects through inhibition of GLI transcription factorsFASEB J20173151916192828148565
   PubMed Web of Science ®Google Scholar
• YuWGuoFSongXEffects and mechanisms of pirfenidone, pred-nisone and acetylcysteine on pulmonary fibrosis in rat idiopathic pulmonary fibrosis modelsPharm Biol201755145045527937011
   PubMed Web of Science ®Google Scholar
• FujiwaraAShintaniYFunakiSPirfenidone plays a biphasic role in inhibition of epithelial-mesenchymal transition in non-small cell lung cancerLung Cancer201710681628285699
   PubMed Web of Science ®Google Scholar
• CantelliGCrosas-MolistEGeorgouliMSanz-MorenoVTGFbeta-induced transcription in cancerSemin Cancer Biol201742606927586372
   PubMed Web of Science ®Google Scholar
• LinRLZhaoLJMechanistic basis and clinical relevance of the role of transforming growth factor-beta in cancerCancer Biol Med201512438539326779375
   PubMed Web of Science ®Google Scholar
• BellomoCCajaLMoustakasATransforming growth factor beta as regulator of cancer stemness and metastasisBr J Cancer2016115776176927537386
   PubMed Web of Science ®Google Scholar
• Felipe LimaJNofech-MozesSBayaniJBartlettJMEMT in breast carcinoma-A reviewJ Clin Med201657E6527429011
   PubMed Web of Science ®Google Scholar
• LiLQiLLiangZTransforming growth factor-β1 induces EMT by the transactivation of epidermal growth factor signaling through HA/CD44 in lung and breast cancer cellsInt J Mol Med201536111312226005723
   PubMed Web of Science ®Google Scholar
• ChenWZhouSMaoLCrosstalk between TGF-beta signaling and miRNAs in breast cancer metastasisTumour Biol2016378100111001927153853
   PubMedGoogle Scholar
• LiZLiuXWangBPirfenidone suppresses MAPK signaling pathway to reverse epithelial-mesenchymal transition and renal fibrosisNephrology (Carlton) Epub20166110.1111/nep.12831
   Web of Science ®Google Scholar
• PangMFGeorgoudakiAMLambutLTGF-β1-induced EMT promotes targeted migration of breast cancer cells through the lymphatic system by the activation of CCR7/CCL21-mediated chemotaxisOncogene201635674876025961925
   PubMed Web of Science ®Google Scholar
• YeYLiuSWuCSunZTGFβ modulates inflammatory cytokines and growth factors to create premetastatic microenvironment and stimulate lung metastasisJ Mol Histol2015464–536537526208571
   PubMed Web of Science ®Google Scholar
• ChenLFuHLuoYcPLA2α mediates TGF-β-induced epithelial-mesenchymal transition in breast cancer through PI3k/Akt signalingCell Death Dis201784e272828383549
   PubMed Web of Science ®Google Scholar
• RuffMLeymeALe CannFThe disintegrin and metalloprotease ADAM12 is associated with TGF-beta-induced epithelial to mesenchymal transitionPLoS One2015109e013917926407179
   PubMed Web of Science ®Google Scholar
• DesaiKAiyappaRPrabhuJSHR+HER2− breast cancers with growth factor receptor-mediated EMT have a poor prognosis and lapatinib downregulates EMT in MCF-7 cellsTumour Biol2017393 101042831769502810.1177/1010428317695028
   Google Scholar
• NooshinfarESafaroghli-AzarABashashDAkbariMEMelatonin, an inhibitory agent in breast cancerBreast Cancer2017241425127017208
   PubMed Web of Science ®Google Scholar
• ZhouYCLiuJYLiJIonizing radiation promotes migration and invasion of cancer cells through transforming growth factor-beta-mediated epithelial-mesenchymal transitionInt J Radiat Oncol Biol Phys20118151530153722115555
   PubMed Web of Science ®Google Scholar
• Mediavilla-VarelaMBoatengKNoyesDAntoniaSJThe antifibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer associated fibroblastsBMC Cancer20161617626935219
   PubMed Web of Science ®Google Scholar
• ChoiSHNamJKJangJLeeHJLeeYJPirfenidone enhances the efficacy of combined radiation and sunitinib therapyBiochem Biophys Res Commun2015462213814325935484
   PubMed Web of Science ®Google Scholar
• KozonoSOhuchidaKEguchiDPirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cellsCancer Res20137372345235623348422
   PubMed Web of Science ®Google Scholar
• TakaiKLeAWeaverVMWerbZTargeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancerOncotarget2016750828898290127756881
   PubMedGoogle Scholar
• PolydorouCMpekrisFPapageorgisPVoutouriCStylianopoulosTPirfenidone normalizes the tumor microenvironment to improve chemotherapyOncotarget2017815245062451728445938
   PubMedGoogle Scholar
• WangXWeiSZhaoYAnti-proliferation of breast cancer cells with itraconazole: Hedgehog pathway inhibition induces apoptosis and autophagic cell deathCancer Lett201738512813627810405
   PubMed Web of Science ®Google Scholar
• Flores-ContrerasLSandoval-RodríguezASMena-EnriquezMGTreatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis CBMC Gastroenterol20141413125064094
   PubMed Web of Science ®Google Scholar
• SzabóRAntiviral therapy and prevention against hantavirus infectionsActa Virol201761131228105849
   PubMed Web of Science ®Google Scholar
• KastRERibavirin in cancer immunotherapies: controlling nitric oxide augments cytotoxic lymphocyte functionNeoplasia2003513812659664
   PubMed Web of Science ®Google Scholar
• DixitNMLayden-AlmerJELaydenTJPerelsonASModelling how ribavirin improves interferon response rates in hepatitis C virus infectionNature2004432701992292415602565
   PubMed Web of Science ®Google Scholar
• NakatsukaKAtsukawaMShimizuMTakahashiHKawamotoCRibavirin contributes to eradicate hepatitis C virus through polarization of T helper 1/2 cell balance into T helper 1 dominanceWorld J Hepatol20157252590259626557951
   PubMedGoogle Scholar
• SiddiquiNSonenbergNSignalling to eIF4E in cancerBiochem Soc Trans201543576377226517881
   PubMed Web of Science ®Google Scholar
• KerekatteVSmileyKHuBSmithAGelderFDe BenedettiAThe proto-oncogene/translation factor eIF4E: a survey of its expression in breast carcinomasInt J Cancer199564127317665244
   PubMed Web of Science ®Google Scholar
• QinXJiangBZhangY4E-BP1, a multifactor regulated multifunctional proteinCell Cycle201615678178626901143
   PubMed Web of Science ®Google Scholar
• WangRGanesanSZhengXFYin and yang of 4E-BP1 in cancerCell Cycle201615111401140227096536
   PubMed Web of Science ®Google Scholar
• MullerDLasfarguesCEl KhawandS4E-BP restrains eIF4E phosphorylationTranslation (Austin)201312e2581926824022
   PubMedGoogle Scholar
• GrzmilMHuberRMHessDMNK1 pathway activity maintains protein synthesis in rapalog-treated gliomasJ Clin Invest2014124274275424401275
   PubMed Web of Science ®Google Scholar
• ArmengolGRojoFCastellvíJ4E-binding protein 1: a key molecular “funnel factor” in human cancer with clinical implicationsCancer Res200767167551755517699757
   PubMed Web of Science ®Google Scholar
• RamalingamSGediyaLKwegyir-AffulAKFirst MNKs degrading agents block phosphorylation of eIF4E, induce apoptosis, inhibit cell growth, migration and invasion in triple negative and Her2-overexpressing breast cancer cell linesOncotarget20145253054324504069
   PubMedGoogle Scholar
• PyronnetSPhosphorylation of the cap-binding protein eIF4E by the MAPK-activated protein kinase Mnk1Biochem Pharmacol20006081237124311007962
   PubMed Web of Science ®Google Scholar
• LuCMakalaLWuDCaiYTargeting translation: eIF4E as an emerging anticancer drug targetExpert Rev Mol Med201618e226775675
   PubMed Web of Science ®Google Scholar
• FanWWangWMaoXElevated levels of p-Mnk1, p-eIF4E and p-p70S6K proteins are associated with tumor recurrence and poor prognosis in astrocytomasJ Neurooncol2017131348549327900644
   PubMed Web of Science ®Google Scholar
• GrzmilMSeebacherJHessDInhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapyCell Signal20162891412142127289018
   PubMed Web of Science ®Google Scholar
• LiSFuJLuCElevated translation initiation factor eIF4E is an attractive therapeutic target in multiple myelomaMol Cancer Ther201615471171926939700
   PubMed Web of Science ®Google Scholar
• KarakiSAndrieuCZiouziouHRocchiPThe eukaryotic translation initiation factor 4E (eIF4E) as a therapeutic target for cancerAdv Protein Chem Struct Biol201510112626572974
   PubMed Web of Science ®Google Scholar
• HuASunMYanDChenKClinical significance of mTOR and eIF4E expression in invasive ductal carcinomaTumori2014100554154625343550
   PubMed Web of Science ®Google Scholar
• DeFattaRJTurbat-HerreraEALiBDAndersonWDe BenedettiAElevated expression of eIF4E in confined early breast cancer lesions: possible role of hypoxiaInt J Cancer19998045165229935150
   PubMed Web of Science ®Google Scholar
• SorrellsDLBlackDRMeschonatCDetection of eIF4E gene amplification in breast cancer by competitive PCRAnn Surg Oncol1998532322379607624
   PubMed Web of Science ®Google Scholar
• NortonKSMcCluskyDSenSTLK1B is elevated with eIF4E overexpression in breast cancerJ Surg Res200411619810314732354
   PubMed Web of Science ®Google Scholar
• HeikkinenTKorpelaTFagerholmREukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatmentBreast Cancer Res Treat20131411798823974830
   PubMed Web of Science ®Google Scholar
• RamonYCajalSDe Mattos-ArrudaLSonenbergNCortesJPegVThe intra-tumor heterogeneity of cell signaling factors in breast cancer: p4E-BP1 and peIF4E are diffusely expressed and are real potential targetsClin Transl Oncol2014161193794125060567
   PubMed Web of Science ®Google Scholar
• LiBDGrunerJSAbreoFProspective study of eukaryotic initiation factor 4E protein elevation and breast cancer outcomeAnn Surg2002235573273811981220
   PubMed Web of Science ®Google Scholar
• McCluskyDRChuQYuHA prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-positive breast cancerAnn Surg2005242458459016192819
   PubMed Web of Science ®Google Scholar
• YinXKimRHSunGMillerJKLiBDOverexpression of eukaryotic initiation factor 4E is correlated with increased risk for systemic dissemination in node positive breast cancer patientsJ Am Coll Surg2014218466367124491247
   PubMed Web of Science ®Google Scholar
• LiZSunYQuMWanHCaiFZhangPInhibiting the MNK-eIF4E-beta-catenin axis increases responsiveness of aggressive breast cancer cells to chemotherapyOncotarget2017822906291527926520
   PubMedGoogle Scholar
• VolpinFCasaosJSesenJUse of an anti-viral drug, ribavirin, as an anti-glioblastoma therapeuticOncogene201736213037304727941882
   PubMed Web of Science ®Google Scholar
• BhatMYanagiyaAGraberTMetformin requires 4E-BPs to induce apoptosis and repress translation of Mcl-1 in hepatocellular carcinoma cellsOncotarget Epub201671810.18632/oncotarget.10671
   Google Scholar
• PonsBPegVVázquez-SánchezMAThe effect of p-4E-BP1 and p-eIF4E on cell proliferation in a breast cancer modelInt J Oncol20113951337134521750861
   PubMed Web of Science ®Google Scholar
• ShiFLenYGongYRibavirin inhibits the activity of mTOR/eIF4E, ERK/Mnk1/eIF4E signaling pathway and synergizes with tyrosine kinase inhibitor imatinib to impair Bcr-Abl mediated proliferation and apoptosis in Ph+ leukemiaPLoS One2015108e013674626317515
   PubMed Web of Science ®Google Scholar
• ZhangYZhengXFmTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitorsCell Cycle201211359460322262166
   PubMed Web of Science ®Google Scholar
• KentsisAVolponLTopisirovicIFurther evidence that ribavirin interacts with eIF4ERNA200511121762176616251386
   PubMed Web of Science ®Google Scholar
• KentsisATopisirovicICuljkovicBShaoLBordenKLRibavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA capProc Natl Acad Sci U S A200410152181051811015601771
   PubMed Web of Science ®Google Scholar
• PetterssonFYauCDobocanMCRibavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancerClin Cancer Res20111792874288421415224
   PubMed Web of Science ®Google Scholar
• PetterssonFDel RinconSVEmondAGenetic and pharmacologic inhibition of eIF4E reduces breast cancer cell migration, invasion, and metastasisCancer Res20157561102111225608710
   PubMed Web of Science ®Google Scholar
• IsakovicAMDulovicMMarkovicIAutophagy suppression sensitizes glioma cells to IMP dehydrogenase inhibition-induced apoptotic deathExp Cell Res20173501324027818246
   PubMed Web of Science ®Google Scholar
• OginoASanoEOchiaiYEfficacy of ribavirin against malignant glioma cell linesOncol Lett2014862469247425364409
   PubMed Web of Science ®Google Scholar
• CriscitielloCGelaoLVialeGEspositoACuriglianoGInvestigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapyExpert Opin Investig Drugs2014235599610
   PubMed Web of Science ®Google Scholar
• YuJMSunWHuaFBCL6 induces EMT by promoting the ZEB1-mediated transcription repression of E-cadherin in breast cancer cellsCancer Lett2015365219020026049022
   PubMed Web of Science ®Google Scholar
• PintoMPDyeWWJacobsenBMHorwitzKBMalignant stroma increases luminal breast cancer cell proliferation and angiogenesis through platelet-derived growth factor signalingBMC Cancer20141473525274034
   PubMed Web of Science ®Google Scholar
• WeigelMTBanerjeeSArnedosMEnhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancerAnn Oncol201324112613322865780
   PubMed Web of Science ®Google Scholar
• Attar-SchneiderODruckerLGottfriedMMigration and epithelial to mesenchymal transition of lung cancer can be targeted via translation initiation factors eIF4E and eIF4GILab Invest20169691004101527501049
   PubMed Web of Science ®Google Scholar
• NasrZRobertFPorcoJAJrMullerWJPelletierJeIF4F suppression in breast cancer affects maintenance and progressionOncogene201332786187122484424
   PubMed Web of Science ®Google Scholar
• RobichaudNdel RinconSVHuorBPhosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3Oncogene201534162032204224909168
   PubMed Web of Science ®Google Scholar
• CunyGDSuebsuwongCRaySSInosine-5′-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature reviewExpert Opin Ther Pat201727667769028074661
   PubMed Web of Science ®Google Scholar
• GuidicelliGChaigne-DelalandeBDilhuydyMSThe necrotic signal induced by mycophenolic acid overcomes apoptosis-resistance in tumor cellsPLoS One200945e549319430526
   PubMed Web of Science ®Google Scholar
• DecarloLMestelCBarcellos-HoffMHSchneiderRJEukaryotic translation initiation factor 4E is a feed-forward translational coactivator of transforming growth factor β early pro-transforming events in breast epithelial cellsMol Cell Biol201535152597260925986608
   PubMed Web of Science ®Google Scholar
• DaiDChenHTangJTangYInhibition of mTOR/eIF4E by anti-viral drug ribavirin effectively enhances the effects of paclitaxel in oral tongue squamous cell carcinomaBiochem Biophys Res Commun201748241259126427932243
   PubMed Web of Science ®Google Scholar
• McHutchisonJGGordonSCSchiffERInterferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy GroupN Engl J Med199833921148514929819446
   PubMed Web of Science ®Google Scholar
• CrabolYCatherinotEVezirisNJullienVLortholaryORifabutin: where do we stand in 2016?J Antimicrob Chemother20167171759177127009031
   PubMed Web of Science ®Google Scholar
• KuninCMAntimicrobial activity of rifabutinClin Infect Dis199622suppl 1S3S138785253
   PubMed Web of Science ®Google Scholar
• LiJHuangYGaoYWuHDongWLiuLAntibiotic drug rifabutin is effective against lung cancer cells by targeting the eIF4E-β-catenin axisBiochem Biophys Res Commun2016472229930526944016
   PubMed Web of Science ®Google Scholar
• NakayamaSSngNCarreteroJβ-catenin contributes to lung tumor development induced by EGFR mutationsCancer Res201474205891590225164010
   PubMed Web of Science ®Google Scholar
• TogashiYHayashiHTerashimaMInhibition of β-Catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer with a T790M mutationJ Thorac Oncol20151019310125384171
   PubMed Web of Science ®Google Scholar
• WeiZGaoWWuYNiBTianYMutual interaction between BCL6 and miRNAs contributing to the pathogenesis of various cancersClin Transl Oncol2015171184184626108407
   PubMed Web of Science ®Google Scholar
• WuQLiuXYanHB-cell lymphoma 6 protein stimulates oncogenicity of human breast cancer cellsBMC Cancer20141441824917186
   PubMed Web of Science ®Google Scholar
• WalkerSRFrankDATargeting BCL6 and STAT3 in triple negative breast cancer: the one-two punch?Oncoscience201521191226697522
   PubMedGoogle Scholar
• ChangCCYeBHChagantiRSDalla-FaveraRBCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressorProc Natl Acad Sci U S A19969314694769528692924
   PubMed Web of Science ®Google Scholar
• EvansSEGoultBTFairallLThe ansamycin antibiotic, rifamycin SV, inhibits BCL6 transcriptional repression and forms a complex with the BCL6-BTB/POZ domainPLoS One201493e9088924595451
   PubMed Web of Science ®Google Scholar
• ZhuZWangSZhuJYangQDongHHuangJMicroRNA-544 down-regulates both Bcl6 and Stat3 to inhibit tumor growth of human triple negative breast cancerBiol Chem2016397101087109527186677
   PubMed Web of Science ®Google Scholar
• GoodmanCRSatoTPeckARSteroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor positive breast cancer through a BCL6-dependent mechanismOncogene201635111373138526096934
   PubMed Web of Science ®Google Scholar
• AnHHeLCurrent understanding of metformin effect on the control of hyperglycemia in diabetesJ Endocrinol20162283R97R10626743209
   PubMed Web of Science ®Google Scholar
• ZouYFXieCWYangSXXiongJPAMPK activators suppress breast cancer cell growth by inhibiting DVL3-facilitated Wnt/beta-catenin signaling pathway activityMol Med Rep201715289990728035400
   PubMed Web of Science ®Google Scholar
• XuHAldrichMCChenQValidating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortalityJ Am Med Inform Assoc201522117919125053577
   PubMed Web of Science ®Google Scholar
• SośnickiSKapralMWęglarzLMolecular targets of metformin antitumor actionPharmacol Rep201668591892527362768
   PubMed Web of Science ®Google Scholar
• GongolBMarinTPengICAMPK exerts its anti-inflammatory effects through PARP-1 and Bcl-6Proc Natl Acad Sci U S A201311083161316623382195
   PubMed Web of Science ®Google Scholar
• QueirozEAPuukilaSEichlerRMetformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cellsPLoS One201495e9820724858012
   PubMed Web of Science ®Google Scholar
• SilvestriAPalumboFRasiIMetformin induces apoptosis and downregulates pyruvate kinase M2 in breast cancer cells only when grown in nutrient-poor conditionsPLoS One2015108e013625026291325
   PubMed Web of Science ®Google Scholar
• WuLZhouBOshiro-RapleyNAn ancient, unified mechanism for metformin growth inhibition in C. elegans and cancerCell201616771705.e131718.e1327984722
   PubMed Web of Science ®Google Scholar
• Ben SahraIRegazzettiCRobertGMetformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1Cancer Res201171134366437221540236
   PubMed Web of Science ®Google Scholar
• GuiDYSullivanLBLuengoAEnvironment dictates dependence on mitochondrial complex I for NAD+ and aspartate production and determines cancer cell sensitivity to metforminCell Metab201624571672727746050
   PubMed Web of Science ®Google Scholar
• ChaeYKAryaAMalecekMKRepurposing metformin for cancer treatment: current clinical studiesOncotarget2016726407674078027004404
   PubMed Web of Science ®Google Scholar
• CoyleCCaffertyFHValeCLangleyREMetformin as an adjuvant treatment for cancer: a systematic review and meta-analysisAnn Oncol201627122184219527681864
   PubMed Web of Science ®Google Scholar
• GadducciABigliaNTanaRCosioSGalloMMetformin use and gynecological cancers: a novel treatment option emerging from drug repositioningCrit Rev Oncol Hematol2016105738327378194
   PubMed Web of Science ®Google Scholar
• ZhangHHGuoXLCombinational strategies of metformin and chemotherapy in cancersCancer Chemother Pharmacol2016781132627118574
   PubMed Web of Science ®Google Scholar
• CazzanigaMBonanniBBreast cancer metabolism and mitochondrial activity: the possibility of chemoprevention with metforminBiomed Res Int2015201597219326605341
   PubMed Web of Science ®Google Scholar
• QuCZhangWZhengGZhangZYinJHeZMetformin reverses multidrug resistance and epithelial-mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cellsMol Cell Biochem20143861–2637124096736
   PubMed Web of Science ®Google Scholar
• SooJSNgCHTanSHMetformin synergizes 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) combination therapy through impairing intracellular ATP production and DNA repair in breast cancer stem cellsApoptosis201520101373138726276035
   PubMed Web of Science ®Google Scholar
• HonjoSAjaniJAScottAWMetformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancerInt J Oncol201445256757424859412
   PubMed Web of Science ®Google Scholar
• HaradaKFerdousTHaradaTUeyamaYMetformin in combination with 5-fluorouracil suppresses tumor growth by inhibiting the Warburg effect in human oral squamous cell carcinomaInt J Oncol201649127628427210058
   PubMed Web of Science ®Google Scholar
• TianYTangBWangCMetformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAPOncotarget2016729462304624127323827
   PubMedGoogle Scholar
• EngelsCCde GlasNASajetAThe influence of insulin-like Growth Factor-1 Receptor expression and endocrine treatment on clinical outcome of postmenopausal hormone receptor positive breast cancer patients: a Dutch TEAM substudy analysisMol Oncol201610450951626706833
   PubMed Web of Science ®Google Scholar
• HadadSIwamotoTJordanLEvidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trialBreast Cancer Res Treat2011128378379421655990
   PubMed Web of Science ®Google Scholar
• NiraulaSDowlingROEnnisMMetformin in early breast cancer: a prospective window of opportunity neoadjuvant studyBreast Cancer Res Treat2012135382183022933030
   PubMed Web of Science ®Google Scholar
• KalinskyKCrewKDReficeSPresurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancerCancer Invest201432415015724605899
   PubMed Web of Science ®Google Scholar
• BonanniBPuntoniMCazzanigaMDual effect of metformin on breast cancer proliferation in a randomized presurgical trialJ Clin Oncol201230212593260022564993
   PubMed Web of Science ®Google Scholar
• CabelloPPinedaBTormoELluchAErolesPThe antitumor effect of metformin is mediated by miR-26a in breast cancerInt J Mol Sci2016178E129827517917
   PubMed Web of Science ®Google Scholar
• ŁabuzekKSuchyDGabryelBBieleckaALiberSOkopieńBQuantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharidePharmacol Rep201062595696521098880
   PubMed Web of Science ®Google Scholar
• LalauJDLemaire-HurtelASLacroixCEstablishment of a database of metformin plasma concentrations and erythrocyte levels in normal and emergency situationsClin Drug Investig2011316435438
   PubMed Web of Science ®Google Scholar
• PantziarkaPBoucheGSukhatmeVMeheusLRoomanISukhatmeVPRepurposing drugs in oncology (ReDO)-propranolol as an anticancer agentEcancermedicalscience20161068027899953
   PubMed Web of Science ®Google Scholar
• MontoyaAAmayaCNBelmontAUse of non-selective beta-blockers is associated with decreased tumor proliferative indices in early stage breast cancerOncotarget2017846446646028031536
   PubMedGoogle Scholar
• CardwellCRPottegårdAVaesEPropranolol and survival from breast cancer: a pooled analysis of European breast cancer cohortsBreast Cancer Res201618111927906047
   PubMed Web of Science ®Google Scholar
• RicoMBaglioniMBondarenkoMMetformin and propranolol combination prevents cancer progression and metastasis in different breast cancer modelsOncotarget2017822874288927926515
   PubMedGoogle Scholar
• BotteriEMunzoneERotmenszNTherapeutic effect of β-blockers in triple-negative breast cancer postmenopausal womenBreast Cancer Res Treat2013140356757523912960
   PubMed Web of Science ®Google Scholar
• HwaYLShiQKumarSKBeta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluationAm J Hematol2017921505527733010
   PubMed Web of Science ®Google Scholar
• ChoyCRaytisJLSmithDDInhibition of β2-adrenergic receptor reduces triple-negative breast cancer brain metastases: the potential benefit of perioperative β-blockadeOncol Rep20163563135314227035124
   PubMed Web of Science ®Google Scholar
• ChildersWKHollenbeakCSCheriyathPβ-blockers reduce breast cancer recurrence and breast cancer death: a meta-analysisClin Breast Cancer201515642643126516037
   PubMed Web of Science ®Google Scholar
• Melhem-BertrandtAChavez-MacgregorMLeiXBeta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancerJ Clin Oncol201129192645265221632501
   PubMed Web of Science ®Google Scholar
• ElefteriouFRole of sympathetic nerves in the establishment of metastatic breast cancer cells in boneJ Bone Oncol20165313213427761374
   PubMed Web of Science ®Google Scholar
• JangHILimSHLeeYYPerioperative administration of propranolol to women undergoing ovarian cancer surgery: a pilot studyObstet Gynecol Sci201760217017728344958
   PubMedGoogle Scholar
• WangTLiYLuHLMengQWCaiLChenXSβ-Adrenergic receptors: new target in breast cancerAsian Pac J Cancer Prev201516188031803926745035
   PubMedGoogle Scholar
• WilsonJMLorimerETyburskiMDWilliamsCLβ-Adrenergic receptor suppress Rap1B prenylation and promote the metastatic phenotype in breast cancer cellsCancer Biol Ther20151691364137426209110
   PubMed Web of Science ®Google Scholar
• IşeriODSahinFITerziYKYurtcuEErdemSRSarialiogluFbeta-Adrenoreceptor antagonists reduce cancer cell proliferation, invasion, and migrationPharm Biol201452111374138125026350
   PubMed Web of Science ®Google Scholar
• KangFMaWMaXPropranolol inhibits glucose metabolism and 18F-FDG uptake of breast cancer through posttranscriptional downregulation of hexokinase-2J Nucl Med201455343944524504055
   PubMed Web of Science ®Google Scholar
• CampbellJPKarolakMRMaYStimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in micePLoS Biol2012107e100136322815651
   PubMed Web of Science ®Google Scholar
• SloanEKPricemanSJCoxBFThe sympathetic nervous system induces a metastatic switch in primary breast cancerCancer Res201070187042705220823155
   PubMed Web of Science ®Google Scholar
• ShaashuaLShabat-SimonMHaldarRPerioperative COX-2 and & beta-adrenergic blockade improves metastatic biomarkers in breast cancer patients in a phase-II randomized trialClin Cancer Res Epub201751010.1158/1078-0432.CCR-17-0152
   Web of Science ®Google Scholar
• WagstaffAJIbbotsonTGoaKLCapecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancerDrugs200363221723612515569
   PubMed Web of Science ®Google Scholar
• WalkoCMLindleyCCapecitabine: a reviewClin Ther2005271234415763604
   PubMed Web of Science ®Google Scholar
• DanieleGGalloMPiccirilloMCPharmacokinetic evaluation of capecitabine in breast cancerExpert Opin Drug Metab Toxicol20139222523523301520
   PubMed Web of Science ®Google Scholar
• RossiDAlessandroniPCatalanoVSafety profile and activity of lower capecitabine dose in patients with metastatic breast cancerClin Breast Cancer200771185786018269775
   PubMed Web of Science ®Google Scholar
• ZielinskiCGralowJMartinMOptimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed?Ann Oncol201021112145215220332132
   PubMed Web of Science ®Google Scholar
• AmbrosTZeichnerSBZaravinosJA retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancerBreast Cancer Res Treat2014146171424899084
   PubMed Web of Science ®Google Scholar
• NishijimaTFSuzukiMMussHBA comparison of toxicity profiles between the lower and standard dose capecitabine in breast cancer: a systematic review and meta-analysisBreast Cancer Res Treat2016156222723626988358
   PubMed Web of Science ®Google Scholar
• AzumaYHataKSaiKSignificant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancerBiol Pharm Bull201235571772422687407
   PubMed Web of Science ®Google Scholar
• KastREErlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectivenessSpringerplus2015463826543772
   PubMedGoogle Scholar
• HarbeckNSaupeSJägerEPELICAN InvestigatorsA randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN studyBreast Cancer Res Treat20171611637227798749
   PubMed Web of Science ®Google Scholar
• EmetMOzcanHOzelLYaylaMHaliciZHacimuftuogluAA review of melatonin, its receptors and drugsEurasian J Med201648213514127551178
   PubMedGoogle Scholar
• KastREAgomelatine or ramelteon as treatment adjuncts in glioblastoma and other M1- or M2-expressing cancersContemp Oncol (Pozn)201519215716226034396
   PubMedGoogle Scholar
• LiuJCloughSJHutchinsonAJAdamah-BiassiEBPopovska-GorevskiMDubocovichMLMT1 and MT2 melatonin receptors: a therapeutic perspectiveAnnu Rev Pharmacol Toxicol20165636138326514204
   PubMed Web of Science ®Google Scholar
• HardelandRPoeggelerBMelatonin and synthetic melatonergic agonists: actions and metabolism in the central nervous systemCent Nerv Syst Agents Med Chem201212318921622640220
   PubMedGoogle Scholar
• PerlemuterGCacoubPVallaDCharacterisation of agomelatine-induced increase in liver enzymes: frequency and risk factors determined from a pooled analysis of 7605 treated patientsCNS Drugs201630987788827342740
   PubMed Web of Science ®Google Scholar
• VriendJReiterRJBreast cancer cells: modulation by melatonin and the ubiquitin-proteasome system – a reviewMol Cell Endocrinol20154171926363225
   PubMed Web of Science ®Google Scholar
• HillSMBelancioVPDauchyRTMelatonin: an inhibitor of breast cancerEndocr Relat Cancer2015223R183R20425876649
   PubMed Web of Science ®Google Scholar
• CosSAlvarez-GarcíaVGonzálezAAlonso-GonzálezCMartínez-CampaCMelatonin modulation of crosstalk among malignant epithelial, endothelial and adipose cells in breast cancerOncol Lett2014848749225009641
   PubMed Web of Science ®Google Scholar
• Sánchez-BarcelóEJCosSMediavillaDMartínez-CampaCGonzálezAAlonso-GonzálezCMelatonin-estrogen interactions in breast cancerJ Pineal Res200538421722215813897
   PubMed Web of Science ®Google Scholar
• MediavillaMDSánchez-BarcelóEJTanDXManchesterLReiterRJBasic mechanisms involved in the anti-cancer effects of melatoninCurr Med Chem2010174462448121062257
   PubMed Web of Science ®Google Scholar
• LopesJArnostiDTroskoJETaiMHZuccariDMelatonin decreases estrogen receptor binding to estrogen response elements sites on the OCT4 gene in human breast cancer stem cellsGenes Cancer201675–620921727551335
   PubMedGoogle Scholar
• NooshinfarEBashashDSafaroghli-AzarAMelatonin promotes ATO-induced apoptosis in MCF-7 cells: proposing novel therapeutic potential for breast cancerBiomed Pharmacother20168345646527427852
   PubMed Web of Science ®Google Scholar
• LopesJRda Silva KavaguttiMMedeirosFADe Campos ZuccariDAEvaluation of melatonin effect on human breast cancer stem cells using a three-dimensional growth method of mammospheresAnticancer Agents Med Chem Epub2016922
   Web of Science ®Google Scholar
• CosSFernándezRGüezmesASánchez-BarcelóEJInfluence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cellsCancer Res19985819438343909766668
   PubMed Web of Science ®Google Scholar
• MaoLSummersWXiangSMelatonin represses metastasis in Her2-positive human breast cancer cells by suppressing RSK2 expressionMol Cancer Res201614111159116927535706
   PubMed Web of Science ®Google Scholar
• MaoLYuanLSlakeyLMJonesFEBurowMEHillSMInhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathwayBreast Cancer Res2010126R10721167057
   PubMed Web of Science ®Google Scholar
• Jardim-PerassiBVArbabASFerreiraLCEffect of melatonin on tumor growth and angiogenesis in xenograft model of breast cancerPLoS One201491e8531124416386
   PubMed Web of Science ®Google Scholar
• SuSCHsiehMJYangWEChungWHReiterRJYangSFCancer metastasis: mechanisms of inhibition by melatoninJ Pineal Res201762110.1111/jpi.12370
   Web of Science ®Google Scholar
• Gonçalves NdoNColomboJLopesJREffect of melatonin in epithelial mesenchymal transition markers and invasive properties of breast cancer stem cells of canine and human cell linesPLoS One2016113e015040726934679
   PubMed Web of Science ®Google Scholar
• RudraDSPalUMaitiNCReiterRJSwarnakarSMelatonin inhibits matrix metalloproteinase-9 activity by binding to its active siteJ Pineal Res201354439840523330737
   PubMed Web of Science ®Google Scholar
• BorinTFArbabASGelaletiGBMelatonin decreases breast cancer metastasis by modulating Rho-associated kinase protein-1 expressionJ Pineal Res201660131526292662
   PubMed Web of Science ®Google Scholar
• Alvarez-GarciaVGonzalezAMartinez-CampaCAlonso-GonzalezCCosSMelatonin modulates aromatase activity and expression in endothelial cellsOncol Rep20132952058206423450505
   PubMed Web of Science ®Google Scholar
• Alvarez-GarciaVGonzalezAAlonso-GonzalezCMartinez-CampaCCosSAntiangiogenic effects of melatonin in endothelial cell culturesMicrovasc Res201387253323473980
   PubMed Web of Science ®Google Scholar
• CosSAlvarez-GarciaVGonzalezAAlonso-GonzalezCMartinez-CampaCMelatonin modulation of crosstalk among malignant epithelial, endothelial and adipose cells in breast cancer (Review)Oncol Lett20148248749225009641
   PubMed Web of Science ®Google Scholar
• WangJXiaoXZhangYSimultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cellsJ Pineal Res2012531779022335196
   PubMed Web of Science ®Google Scholar
• Martínez-CampaCMenéndez-MenéndezJAlonso-GonzálezCGonzálezAAlvarez-GarcíaVCosSWhat is known about melatonin, chemotherapy and altered gene expression in breast cancerOncol Lett20171342003201428454355
   PubMed Web of Science ®Google Scholar
• MaCLiLXZhangYProtective and sensitive effects of melatonin combined with adriamycin on ER+ (estrogen receptor) breast cancerEur J Gynaecol Oncol201536219720226050360
   PubMed Web of Science ®Google Scholar
• GaoYXiaoXZhangCMelatonin synergizes the chemotherapeutic effect of 5-fluorouracil in colon cancer by suppressing PI3K/AKT and NF-κB/iNOS signaling pathwaysJ Pineal Res201762210.1111/jpi.12380
   Web of Science ®Google Scholar
• ParienteRParienteJARodríguezABEspinoJMelatonin sensitizes human cervical cancer HeLa cells to cisplatin-induced cytotoxicity and apoptosis: effects on oxidative stress and DNA fragmentationJ Pineal Res2016601556426462739
   PubMed Web of Science ®Google Scholar
• UguzACCigBEspinoJMelatonin potentiates chemotherapy-induced cytotoxicity and apoptosis in rat pancreatic tumor cellsJ Pineal Res2012531919822288984
   PubMed Web of Science ®Google Scholar
• Ruiz-RabeloJVázquezRArjonaAImprovement of capecitabine antitumoral activity by melatonin in pancreatic cancerPancreas201140341041421178648
   PubMed Web of Science ®Google Scholar
• ZhelevZIvanovaDBakalovaRAokiIHigashiTSynergistic cytotoxicity of melatonin and new-generation anticancer drugs against leukemia lymphocytes but not normal lymphocytesAnticancer Res201737114915928011485
   PubMed Web of Science ®Google Scholar
• Alonso-GonzálezCGonzálezAMartínez-CampaCMelatonin enhancement of the radiosensitivity of human breast cancer cells is associated with the modulation of proteins involved in estrogen biosynthesisCancer Lett2016370114515226497762
   PubMed Web of Science ®Google Scholar
• LuJJFuLTangZMelatonin inhibits AP-2beta/hTERT, NF-kB/COX-2 and Akt/ERK and activates caspase/Cyto C signaling to enhance the antitumor activity of berberine in lung cancer cellsOncotarget2016732985300126672764
   PubMedGoogle Scholar
• CalvoJRGonzález-YanesCMaldonadoMDThe role of melatonin in the cells of the innate immunity: a reviewJ Pineal Res201355210312023889107
   PubMed Web of Science ®Google Scholar
• DevoreEEWarnerETEliassenAHUrinary melatonin in relation to postmenopausal breast cancer risk according to melatonin 1 receptor statusCancer Epidemiol Biomarkers Prev201726341341928151704
   PubMed Web of Science ®Google Scholar
• BaslerMJetterAFinkDSeifertBKullak-UblickGATrojanAUrinary excretion of melatonin and association with breast cancer: meta-analysis and review of the literatureBreast Care (Basel)20149318218725177260
   PubMed Web of Science ®Google Scholar